CPT® Code 90664

1. Indications

The influenza virus vaccine, live (LAIV), pandemic formulation, is indicated for use in individuals during an influenza pandemic. The primary purpose of this vaccine is to provide immunity against a new strain of the influenza virus that has emerged and is spreading within the human population. The vaccine is particularly important for individuals who may have little or no pre-existing immunity to the new strain, thereby reducing the risk of severe illness and complications associated with the outbreak.

• Influenza Pandemic The vaccine is indicated for individuals during an influenza pandemic when a new strain of the virus is circulating.
• Immunity Enhancement It is used to enhance the immune response in individuals who may lack immunity to the new influenza strain.

2. Procedure

The administration of the influenza virus vaccine, live (LAIV), involves specific procedural steps to ensure effective delivery and immune response. The following steps outline the procedure:

• Step 1: Preparation Prior to administration, the vaccine should be prepared according to the manufacturer's instructions. This includes ensuring that the vaccine is stored at the appropriate temperature and is not expired.
• Step 2: Patient Assessment A thorough assessment of the patient should be conducted to confirm eligibility for the vaccine, including reviewing any contraindications or previous adverse reactions to influenza vaccines.
• Step 3: Administration The vaccine is administered intranasally, typically as a nasal spray. The patient is instructed to inhale the vaccine mist through their nose, which allows the live attenuated virus to stimulate the immune system effectively.
• Step 4: Post-Administration Monitoring After administration, the patient should be monitored for a short period to observe for any immediate adverse reactions, although serious reactions are rare.

3. Post-Procedure

Post-procedure care for the administration of the LAIV vaccine includes advising the patient on potential mild side effects, which may include nasal congestion, runny nose, or mild fever. Patients should be informed that these symptoms are generally self-limiting and indicate that the immune system is responding to the vaccine. It is also important to instruct patients to report any unusual or severe reactions following vaccination. Additionally, patients should be advised to continue practicing preventive measures against influenza, such as hand hygiene and avoiding close contact with sick individuals, especially during flu season.